Sight-Threatening Condition in Severe Thyroid Eye Disease: How We Should Manage

Yunia Irawati, Dewi Megasari Juhrie, Carennia Paramita, Darmayanti Siswoyo, Hernawita Suharko, Laurentius Aswin Pramono

Abstract


Thyroid eye disease (TED) is an autoimmune disorder that is associated with thyroid gland dysfunction which causes muscle and orbital fat enlargement. This case report is aimed to present a case of sight-threatening TED and how we should manage this condition. We present a case of patient with chief complaint of vision loss and prominent eyes for 5 months prior to the visit to our eye hospital. Patient had sought advice from an ophthalmologist and internist. TED was eventually diagnosed 2 months after consulted with an ophthalmologist in the rural area. According to EUGOGO guidelines, TED with sight-threatening condition should be treated with glucocorticoid IV 500-1000 mg for 3 days consecutively. Although the patient was already given steroid injection for the initial treatment, the dosage was inadequate. After the inflammation process was reduced, the patient was reluctant to have an orbital decompression that was suggested. Hence, TED progressed continuously besides sight-threatening complications arising. He indeed underwent fat decompression and tarsorrhaphy as eyelid surgery to prevent corneal exposure. In follow-up, both visual acuity and corneal improvement were finally achieved. In the management of TED, collaboration between ophthalmologist and internist, who may be specialized in endocrinology, is imperative. They should be able to manage TED promptly and correctly, hence sight-threatening and other complications can be prevented and satisfactory results are achieved. Fat decompression should be considered as a good help to improve visual acuity nevertheless orbital decompression cannot be done.


Keywords


grave’s disease; thyroid eye disease; dysthyroid optic neuropathy; orbital decompression; fat decompression

References


Bahn RS. Grave’s ophthalmopathy. N Engl J Med 2010;362:762-38.

Fay A, Dolman PJ, Bahn RS, Kazim M. Diseases and disorders of the orbit and ocular adnexa. Thyroid eye disease. Boston: Elsevier; 2016.p.219-34.

Foster JA, Carter KD, Durairaj VD, Kavanagh MC, Korn BS, Nelson CC, et al. Orbit, eyelids, and lacrimal system. Orbital inflammatory and infectious disorder. In: Cantor LB, Rapuano CJ, Cioffi GA. American Academy of Ophthalmology section 7. San Fransisco: LEO; 2012.p.47-55.

Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velazquez-Villoria A, Galofre JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol 2015;15:1-12.

Nair AG, Desai ST. An algorithmic approach in the diagnosis and management of thyroid eye disease. J Clin Ophthalmol Res 2015;3(2):113-9.

Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 2016;5:9-26.

Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 2018;7:167-86.

Lantz M, Planck T, Asman P, Hallengren B. Increased TRAb and/ or low anti-TPO titers at diagnosis of Graves’ disease are associated with an increased risk of developing ophthalmopathy after onset. Exp Clin Endocrinol Diabetes 2014;122:113-7.

Bartalena L. Grave’s orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J 2013;2:259-69.

Katsuyama T, Takeda M, Otsuka F, et al. Rapid progression of Grave’s ophthalmopathy despite the administration of thiamazole. Int Med 2013;52:2317-20.

Yen MT. Imaging in thyroid ophthalmopathy [internet]. USA: Medscape [updated 2016 Jan 13; cited 2018 Nov 22]. Available from: https://emedicine.medscape.com/article/383412-overview.

Penne RB, Rapuano CJ. Wills eye hospital – color atlas and synopsis of clinical ophthalmology. Thyroid eye disease; China: Wolters Kluwer. 2018.p.166-71.

Wiersinga WM, Kahaly AGJ. Graves’ orbitopathy. A multidisciplinary approach – questions and answers: Management of very severe graves’ orbitopathy (dysthyroid optic neuropathy and corneal breakdown). Switzerland: Karger; 2010.p.159-66.

Wiersinga WM. Graves’ orbitopathy: management of difficult cases. Indian J Endocr Metab 2012;16(2):150-2.

Pinto CN. Current protocol for the management of thyroid eye disease. DOS Times [Internet]. India: Management protocol oculoplasty [updated 2015 Apr 10; cited 2018 Nov 22]. Available from: http://www.dos-times.org/pulsar9088/20150507173851069.pdf.

American Academy of Ophthalmology. Tarsorrhaphy [Internet]. USA: American Academy of Ophthalmology [updated 2018; cited 2018 Nov 22]. Available from: https://www.aao.org/bcscsnippetdetail.aspx?id=3c2b27d8-c930-4a31-8036-9ce3dcebaf61.

Rajak S, Rajak J, Selva D. Performing tarsorrhaphy. Community Eye Health J 2015;28(89):10-1.

Palace MR. Perioperative management of thyroid dysfunction. Health Serv Insights 2017;1-5.

Mercandetti M. Orbital decompression for Graves’ disease [Internet]. USA: Medscape [updated 2018 Oct 19; cited 2018 Dec 2]. Available from: https://emedicine.medscape.com/article/878672-overview.

Vaphiades M. Graves’-related blindness reversible with decompression surgery [Internet]. USA: American Academy of Ophthalmology [updated 2014 Mar 24; cited 2018 Dec 3]. Available from: https://www.aao.org/editors-choice/orbital-decompression-compressive-optic-neuropathy.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.